Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the pharmaceutical industry.

“Meryl Zausner is a highly accomplished financial and strategic leader, and I am delighted to welcome her to the Seres Board,” said Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres. “Meryl’s extensive biopharmaceutical and oncology expertise will be an important asset to Seres as we continue to advance our extensive pipeline of microbiome therapeutic candidates.”

Ms. Zausner commented: “I am eager to contribute to Seres’ progress as it advances the development of microbiome therapeutics, a promising new treatment modality with potential to address a wide range of serious diseases.”

Meryl Zausner previously served as chief financial and administrative officer of Novartis Pharmaceuticals Corporation and a member of the U.S. Pharmaceutical Executive Committee and Global Finance Leadership Team. At Novartis, she was instrumental in the launch of the Oncology Business Unit, as well as the company’s shared services organization. Ms. Zausner was a member of the Novartis Global Oncology Leadership Team and played a key role in developing and commercializing leading therapies including Gleevec (imatinib). Ms. Zausner is also currently a board member and chair of the audit committee for Neon Therapeutics, Inc. and the Multiple Myeloma Research Foundation. Ms. Zausner received a B.S. in accounting and economics from the University at Albany, SUNY.